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Dendrimer represents hyperbranched, monodisperse, three-dimensional 
macromolecules with host-guest entrapment properties having defined molecular weight. 
Dendrimer allows defined control of size, shape and position of functional groups. For 
the above said reason, dendrimers have become more popular application in many 
fields.The present study was aimed at developing and exploring the use of novel 
PEGylated 0.5G EDA-PPI (poly propyeleneimine) dendritic architecture for the delivery 
of an antibacterial drug, Ofloxacin. The dendritic architecture was synthesized by double 
Michael addiction reaction using ethylenediamine as a core moiety and the synthesized 
system was PEGylated using PEG-4000 and the Ofloxacin was loaded by equilibrium 
dialysis method into the system. The prepared Ofloxacin loaded PEGylated 0.5G EDA-
PPI dendritic architecture was evaluated for FTIR studies, solubility studies, drug 
entrapment efficiency, in-vitro drug release studies and anti-bacterial assay. The results 
showed that there was enhanced rate of drug release, drug solubility with significant 
antimicrobial activity compared to plain Ofloxacin. The tablets of Ofloxacin loaded 
PEGylated 0.5G EDA-PPI dendrimer were prepared by direct compression method and 
evaluated for various parameters such as hardness, thickness, weight variation, drug 
content and in-vitro drug release studies. The in-vitro drug release of Ofloxacin loaded 
0.5G EDA-PPI dendrimer compared with that of marketed Ofloxacin tablet. The results 
revealed that there is enhanced rate of dissolution of Ofloxacin loaded PEGylated 0.5G 
EDA-PPI dendrimer than that of marketed Ofloxacin tablet formulation. 
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INTRODUCTION 
Development of bacterial resistance to currently available antibacterial drugs by 
either new mutations or the exchange of genetic information, that is, putting old resistance 
genes into new hosts is very common. In many healthcare facilities around the world, 
bacterial pathogens that express multiple resistance mechanisms are becoming the norm, 
complicating treatment and increased both human morbidity and financial costs. 
About forty percent of newly developed drugs are rejected by the pharmaceutical 
industry and will never benefit a patient because of poor bioavailability due to low water 
solubility and/or cell membrane permeability. New delivery technologies could help to 
overcome this challenge. Nanostructures with uniform and well-defined particle size and 
shape are of eminent interest in biomedical applications because of their ability to cross cell 
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membranes and to reduce the risk of premature clearance from the body. The high level of 
control over the dendritic architecture (size, branching density, surface functionality) makes 
dendrimers ideal carriers in these applications. These have unique characteristics including 
monodispersity and modifiable surface functionality, along with highly defined size and 
structure constituted of three distinct domains: (i) a central core which is either a single atom 
or an atomic group having at least two identical chemical functions, (ii) branches emanating 
from the core, constituted of repeat units having at least one branch junction, whose 
repetition is organized in a geometrical progression that results in a series of radially 
concentric layers called generations, and (iii) many terminal functional groups, generally 
located in the exterior of the macromolecule, which play a key role in the properties. This 
makes these polymers attractive candidates as carriers in drug delivery applications. Many 
commercial small drug molecules with anticancer, anti-inflammatory, and antimicrobial 
activity have been successfully associated with Dendrimers (Sushma et al., 2010). Drug 
delivery can be achieved by coupling a drug to polymer through one of two approaches. 
Hydrophobic drugs can be complexed within the hydrophobic dendrimer interior to make 
them water-soluble or drugs can be covalently coupled onto the surface of the dendrimers. 
The loading ability of drug molecules and other bioactive agents can be altered by varying 
dendrimer generations, the water solubility, biodistribution, circulation time in blood and 
therapeutic efficiency of drugs in dendrimer-based formulations can be tuned by varying 
dendrimer surface components, the release of drugs from dendrimer scaffolds can be 
controlled by using different degradable linkers between dendrimers and drugs, and the 
specific accumulation of the dendrimer-based therapeutics can be achieved by further 
modifying the dendrimers with targeting moieties. These properties together prove 
dendrimer perfect candidate in the design of new drug delivery systems (Mishra, 2011). 
Dendrimers are repeatedly branched macromolecules or nano-sized, radially 
symmetric molecules with well-defined, homogeneous and mono-disperse structure 
consisting of tree-like arms or branches. The name comes from the~Greek~word Dendron 
which translates to tree. Dendrimers are globular or spheroid nanostructures that are 
engineered to encapsulate the molecules into their interior void spaces or to attach onto the 
surface (Nanjwade et al., 2009) 
Although dendrimers have vast application in biomedical field, their use is restricted 
due to RES uptake, drug leakage, immunogenicity, stability, hemolytic toxicity, 
hydrophobicity etc. PEGylation of dendrimers can generally overcome these limitations. 
Polyethylene glycol (PEG) conjugation or linking with the dendritic system is called 
PEGylation. This can, in addition, increase the solubility of hydrophobic drugs. The term 
PEG is used for polyethylene glycol, which is often referred for polymer chains with a 
molecular weight below 20,000. Poly ethylene glycol (PEG) is typically a clear, colorless, 
odourless substance that is soluble in water, stable to heat, inert to many chemical agents, 
that does not hydrolyze or deteriorate, and is generally non-toxic, PEG is considered to be 
biocompatible, which is to say that PEG is capable of coexistence with living tissue or 
organisms without causing harm. It has been shown that covalent attachment of poly 
(ethylene glycol) to proteins decreases their immunogenicity and increases their circulation 
time. Moreover, a number of studies have demonstrated that poly (ethylene glycol) chains 
grafted to surface of polymer micelles and liposomes suppress their interaction with plasma 
proteins and cells and prolong their blood elimination half-life. On the basis of these 
findings, it seems that dendrimers covered with poly (ethylene glycol) grafts are attractive 
compounds as drug carriers in in-vivo. Such molecules are expected to encapsulate drugs in 
their dendrimer moiety and reveal biocompatibility due to their hydrophilic shell consisting 
of poly (ethylene glycol) grafts (Virendra et al., 2007; Roberts  et al., 2002). 
The present study was aimed at developing and exploring the use of novel 
PEGylateddendritic architecture for the delivery of anti-bacterial drug Ofloxacin. 
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MATERIALS AND METHODS: 
Materials used: PEG 4000, Dimethyl sulphoxide, 4-Dimethyl amino pyridine, Dioxane, 
Triehylamine and Acrylonitrile was purchased from Himedia laboratories Pvt Ltd, Mumbai, 
India. Ethylene diamine and N, N- Dicyclohexylcarbodimide was purchased from 
Lobachemie, India. Cellulose dialysis bag (MWCO 12-14kda) was purchased from Himedia 
laboratories Pvt Ltd, Mumbai, India. Ofloxacin (OFL) was purchased from Yarrow chemical 
Mumbai, India. All other materials were used are of analytical grade. 
 
Methods:  
Construction of standard calibration curve for Ofloxacin in different solutions 
Preparation of stock solution of Ofloxacin (OFL) in Methanol:- 
50 mg of pure Ofloxacin was weighed and transferred to 100 ml volumetric flask. 
Ofloxacin was dissolved in 35 ml methanol by gentle shaking and volume was made up to 
the mark with methanol to obtain final concentration of 500 µg/ml and labeled as ‘Std Stock 
solution I’. From the ‘Std Stock solution I’ 2 ml of aliquot was pipetted out in a 25 ml 
volumetric flask and the volume was made up to the mark with methanol to obtain final 
concentration of 40 µg/ml and labeled as ‘Std Stock solution II’ (Gandhi et al., 2013). 
Determination of λ max of Ofloxacin in Methanol:- 
From the above Std stock solution II aliquot of 2.5ml was pipetted out in a 10ml 
volumetric flask and volume was made up to the mark with methanol to obtain 10 µg/ml of 
drug solution. UV scanning was done for this 10 µg/ml of drug solution between 200-400nm 
using methanol as a blank in UV/ VIS spectrophotometer. The wavelength maximum was 
found to be 295nm. 
Construction of calibration curve of Ofloxacin in Methanol:- 
From the above Std stock solution II aliquots of 0.5, 1, 1.5, 2.0, 2.5 and 3ml was 
pipetted out and transfer to 10 ml volumetric flask and volume was made up to the mark 
with methanol to get working standards of 2-12µg/ml. The absorbance of these solutions 
was measured at 295nm against methanol as a blank. Calibration curve was constructed by 
plotting concentration versus absorbance. 
Construction of standard calibration curve of Ofloxacin in 0.1N HCl buffer:- 
The standard stock solution of Oflaxacin was prepared by transferring accurately 
weighed 10 mg of drug to 10 ml volumetric flask and dissolving it with 0.1N HCl to get a 
concentration of 1000 µg/ml. The solution was diluted accordingly to get a concentration of 
100µg/ml and was kept as the stock solution. The prepared stock solution was diluted with 
0.1N HCl solution to get working standard solutions of concentrations 02-12 µg/ml (Arun et 
al., 2011). 
Determination of λ max of Ofloxacin in 0.1N HCl:- 
The standard solution of Ofloxacin (10 µg/ml) was scanned in the wavelength region 
of 200-400 nm and the λmax was found to be 297 nm. 
Preparation of standard calibration curve of Ofloxacin in 0.1N HCl:- 
The working standard solutions of Ofloxacin were scanned in the UV region and the 
absorbances were observed against 0.1N HCl solution as blank at 297nm. Finally the 
calibration curve was plotted between concentration (x-axis) and absorbance (y-axis). 
 
SYNTHESIS OF OFLOXACIN LOADED DENDRITIC ARCHITECHTURE:- 
Synthesis of 0.5G EDA-PPI Dendrimers:-  
The half generation EDA-dendrimer-(CN) 4n (where n is generation of reaction or 
reaction cycle) was synthesized by double Michael addiction reaction between acrylonitrile 
(2.5 molar times per terminal NH2 group of core amine moiety) and aqueous solution of 
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ethylenediamine or previous full generation dendrimers. After the initial exothermic phase, 
the reaction mixture was heated at 80ºC for 1 h to complete the addiction reaction. The 
excess of acrylonitrile was then removed by vaccum distillation (Bhadraet al., 2005) 
NH2
NH2 +
N
N N
N
N
N
N
Ethylenediamine (1mole)   Acrylonitrile (5 mole)                  0.5 G Nitrile terminal 
 
Synthesis of PEGylated 0.5G EDA-PPI Dendrimers:- 
To a solution of 0.5G EDA-PPI dendrimer (0.01 mmol) in dimethyl sulfoxide (DMSO) (10 
ml), PEG 4000 (0.32 mmol) in DMSO (10 ml) and N, N dicyclohexylcarbodiimide (DCC) 
(0.32 mmol) in DMSO (10 ml) were added and the solution was stirred for 5 days at room 
temperature. The product was precipitated by addition of water, filtered and dialyzed 
(MWCO 12-14 Kda, Himedia, India) against double distilled water for 24 h to remove free 
PEG 4000, DCC and partially PEGylateddendrimers (Reddy et al., 2012) 
 
Drug Loading in Formulation:- 
The loading of drug was carried out by equilibrium dialysis method. The known molar 
concentrations of PEGylated 0.5G dendrimers was dissolved separately in methanol and 
mixed with methanolic solution of Ofloxacin (2 mol). The mixed solutions were incubated 
with slow magnetic stirring (50 rpm) using teflon beads for 24 h. These solutions were twice 
dialyzed in cellulose dialysis bag against double distilled water under sink conditions for 10 
min to remove free drug from the formulations, which was then estimated 
spectrophotometrically to determine indirectly the amount of drug loaded within the system 
(Gajbhiye et al., 2008). 
 
CHARACTERIZATION OF PREPARED DENDRITIC ARCHITECHTURE:- 
Fourier Transform Infrared Spectroscopy (FTIR):- 
The prepared half generation EDA-PPI dendrimer was subjected for FTIR for detection of 
functional groups which proves the development of dendritic architechture. The drug-
loaded dendrimer was also subjected for FTIR to check drug-dendrimer compatibility. 
 
In-vitro Drug Release:- 
 The drug release from the known amount of OFL loaded PEGylated 0.5G EDA-PPI 
Dendrimers were determined by using 0.1N HCl as a dissolution medium. The dialysis bag 
were filled with a known amount of OFL loaded PEGylated 0.5G PPI Dendrimers and were 
placed in 50 ml of 0.1N HCl at 37±20C with slow magnetic stirring under sink conditions. 
Aliquots of 1 ml were withdrawn from the external solution and replenished with an equal 
volume of fresh media. The drug concentration was detected by UV spectrophotometer at 
297nm λmax (Gajbhiyeet al., 2008). 
 
Antibacterial assay (Agar well diffusion method):- 
Two human pathogenic bacteria Staphylococcus aureus and E.coli were tested against the 
Ofloxacin loaded dendrimer. The antimicrobial activity of Ofloxacin loaded dendrimer was 
determined by agar well diffusion method against different bacteria as described. In this 
method, pure isolate of each bacterium was sub-cultured in nutrient broth at 37ºC for 24h. 
One hundred microliters of each test bacterium was spread with the help of sterile spreader 
on to a sterile Muller-Hinton Agar plate so as to achieve a confluent growth. The plates were 
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allowed to dry and a sterile cork borer of diameter 6.0mm was used to bore wells in the agar 
plates. Subsequently, a 50µL volume of the dendrimer, pure Ofloxacin and drug loaded 
dendrimer was introduced in triplicate wells into Muller-Hinton Agar plate. The plates were 
allowed to stand for 1h or more for diffusion to take place and then incubated at 37ºC for 
24h. The zone of inhibition was recorded to the nearest size in mm. (Reddy et al., 2012). 
 
Determination of solubility of Ofloxacin loaded dendrimercomplex:- 
 The solubility study of Ofloxacin loaded dendrimer complex was determined by 
adding an excess amount of dendrimer-drug complex (Equivalent to10 mg of drug) to 10 ml 
of different solvents in conical flasks. The flasks were kept at 37±0.50 0C on mechanical 
shaker for 24 hrs to reach equilibrium. The samples were removed from shaker and filtered 
through whatmann filter paper. The concentration of OFL was determined from samples 
after suitable dilution by using UV- visible spectrophotometer at 295nm (Shyamala, 2003). 
 
Preparation of tablets containing Ofloxacin loaded dendrimer by direct compression 
method:- 
The tablets of Ofloxacin loaded EDA-PPI dendrimer was prepared by direct compression 
technique. About 5 gm of Ofloxacin was loaded in 0.5G EDA-PPI dendrimer by method 
mentioned above. The dried powder was directly used for the preparation of tablets by 
mixing it with Micro crystalline cellulose, Magnesium stearate and Talc in a geometric ratio 
and passed through sieve no. 60. The powder blend was subjected to preformulation studies 
prior to compression. 
Table 1. Formulation chart for tablet 
Ingredients (mg) F0 F1 
Ofloxacin 200 0 
Ofloxacin loaded 0.5 EDA-PPI dendrimer 
equivalent to 200mg of Ofloxacin 
0 300 
MCC 150 50 
Mg. stearate 25 25 
Talc 25 25 
 
Tablet compression 
The tablets were compressed by using single-station tableting machine. The compressible 
weight of each tablet was 500 mg. The tablet was compressed using 6 mm flat-faced 
punches. The hardness was adjusted to 2.5 to 3.0 kg/cm2. 
Preformulation Studies of Powder Blend- 
Different preformulation studies such as angle of repose, bulk density, tapped density, carr’s 
index, hausner’s ratio of powder blend were carried out (Upendra et al., 2011; Lakshmi  et al., 
2011). 
Evaluation of Tablets 
Tablets were evaluated for different post compressional parameters such as hardness, 
thickness, friability, weight variation, in-vitro disintegration and in-vitro drug release studies 
(Rakesh et al., 2011; Nagendrakumar et al., 2010; Kathiresan et al., 2010). 
Stability study:  
The prepared tablet formulation and drug loaded 0.5G EDA-PPI dendrimer were subjected 
to stability studies as per I.C.H. Guidelines (ICH guidelines Q1A, 2011). 
Following conditions were used for stability studies 
 30 0C/65 % RH analyzed at a time interval of 30 days till a period of 60 days 
 40 0C/75 % RH analyzed at a time interval of 30 days till a period of 60 days 
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RESULT AND DISCUSSION 
Determination of λmax 
The drug was identified by the light absorption in the U.V range of 400-200 nm. The 
absorbance of drug solutions (10mcg/ml) was measured at λmax 295nm with methanol as a 
solvent and 297nm with 0.1N HCl as solvent. This was in accordance with reported values. 
The results were shown in Figure 1 and 2. 
 
 
Figure 1: UV-Spectrum of Ofloxacin in Methanol (10µg/ml) 
 
Figure 2: UV-Spectrum of Ofloxacin in 0.1N HCl (10µg/ml) 
 
Standard plot of Ofloxacin in Methanol at λmax 295nm  
 
 
 
Figure 3: Standard plot of Ofloxacin in Methanol at 295 nm 
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Figure 6: FTIR spectra of 0.5G EDA-PPI Dendrimer 
 
Table 3: FTIR frequencies in 0.5G EDA-PPI Dendrimer 
 
 
 
 
 
 
 
 
 
 
Wavenumber [cm-1] 
Figure 7: FTIR spectra of Ofloxacin and Dendrimer 
Sr. no Functional Group 
Reported 
Frequency 
cm-1 
Observed 
Frequency 
cm-1 
1 CN 2250 2281 
2 C-H  1260 1255.43 
3 N-H 3400-3500 3488.6 
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Table 4: FTIR frequencies in Ofloxacin and Dendrimer 
 
 
 
 
 
 
 
 
 
 
The IR spectra of the drug loaded dendrimer formulation was compared with the standard 
spectrum of pure drug Ofloxacin and the characteristic peaks associated with specific 
functional groups and bonds of the molecule and their presence/absence were noted. 
The prominent peaks associated with C=0, C-H, C-F, N-H and benzene ring (alone 
and with dendrimer) were analysed.  
The range of peak values were found to be the same indicating that there were no 
interaction of Ofloxacin with dendrimer confirming the stability of drug in the formulations. 
 FTIR peak mainly of nitrile at 2281 cm-1, confirmed synthesis of half generation poly 
propylene imine dendrimer(Figure 6). 
 
Drug loading in the Formulation 
 Table 5: Drug Loading in the Formulation 
 
 
 
 
The non-covalent interaction between Ofloxacin and PEGylated EDA-PPI 0.5G 
dendrimes, such as hydrophobic interaction and hydrogen bonding contributed to the 
physical binding of drug molecules inside the dendritic micelles and surface of PEG layers. 
PEGylation increases the Ofloxacin loading capacity of the 0.5G PPI dendrimers due to the 
more interaction of drug and PEG at the peripheral portions of Dendrimers. Number of 
Ofloxacin moles entrapped in one mole of PEGylated dendritic architecture was found to be 
71.59±1.45 moles. 
 
In-vitro drug release study of Ofloxacin loaded PEGylated 0.5G EDA-PPI dendrimer:- 
 
 
Figure 8.In vitro release of Ofloxacin loaded PEGylated 0.5G EDA-PPI dendrimer 
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minedendrimer is an effective carrier to target any antibacterial agent for resistant 
producing organism. 
 
Table 6 Antibacterial activity of Ofloxacin loaded Dendrimers against resistant producing 
microorganism 
NZI-No zone of Inhibition; DLD- Drug loaded dendrimer; DMSO- Dimethyl sulphoxide.  
Average of three trials (n=3); Zone of inhibition in mm 
 
Determination of solubility of Ofloxacin loaded Dendrimer complex 
 
 
 
Figure 15. Comparison of solubility of plain OFL and OFL loaded dendrimer 
complex 
The solubility study of OFL loaded dendrimer complex was determined by adding an excess 
amount of dendrimer-drug complex (Equivalent to10 mg of drug) to 10 ml of different 
solvents such as 0.1N HCl, Water and Methanol and compared with plain Ofloxacin. The 
results revealed that the solubility of OFL loaded dendrimer complex shows better solubility 
than that of plain Ofloxacin. The results are shown in Figure 15. 
 
PREFORMULATION STUDIES OF POWDER BLEND 
 
Table 7.Micromeritic properties of pre-compressional powder blend. 
 
All values are expressed as mean ± SD, n=3 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0.1N HCl Methanol Water
DLD
OFL
S. No Treatment Staphylococcus aureus E-coli 
1. Control (DMSO) NZI NZI 
2. Standard (Ofloxacin 100µg/ml) 16.25±0.15 18.3±0.25 
3. DLD (100µg/ml) 26.7±0.23 28.48±0.1 
Batch 
no. 
Angle of 
repose (Ө)± 
SD 
Bulk Density 
(gm/cc)± SD 
Tapped Density 
(gm/cc)± SD 
Hausner’s 
Ratio± SD 
Carr’s Index 
(%)± SD 
F0 28.54±0.54 0.2772±0.3045 0.4021±0.0035 1.241±0.0025 18.63±0.853 
F1 27.63±0.53 0.293±0.2957 0.3468±0.0063 1.226±0.0079 16.77±0.411 
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EVALUATION OF OFLOXACIN LOADED DENDRIMER TABLETS 
Table 8(A). Evaluation of Ofloxacin Loaded Dendrimer Tablets 
 
 
 
 
 
 
All values are expressed as mean ± SD, n = 10+, 20* 
 
Table 8(B). Evaluation of Ofloxacin Loaded Dendrimer Tablets 
 
 
 
 
 
All values are expressed as mean ± SD, n = 20† 
 
In-vitro drug release study of Ofloxacin loaded dendrimer tablets 
 
 
Figure16.In-vitro drug release study of Ofloxacin loaded dendrimer tablets and plain 
Ofloxacin tablets 
 
Comparison of Dissolution profile of Ofloxacin loaded dendrimer tablet with Marketed 
Ofloxacin Tablet 
Both the formulations were subjected for in vitro dissolution studies using tablet 
dissolution tester USP type II in 900 ml of 0.1N HCl buffer pH 1.2 dissolution medium at 50 
rpm at 37oC ± 0.5oC. The percentage of Ofloxacin released as a function of time for F0 is 
73.09±0.35 for 60 mins. The percentage of Ofloxacin released as a function of time for 
formulation F1 was found to be 94.77±0.57 for 60 mins. The rapid drug dissolution was 
observed in F1 because the protonation of primary as well as tertiary amine groups in PPI 
dendrimer affects size and density of the dendrimer molecule, which contributed to faster 
release of drug at lower pH. The in-vitro drug release studies of formulation F0 and F1 is 
depicted in Figure 16.  
 The in-vitro dissolution studies of formulation F1 was compared with plain Ofloxacin 
conventional tablet available in market. The study shows better dissolution profile of 
Ofloxacin loaded 0.5G EDA-PPI dendrimer tablet i.e. formulation F1 than that of marketed 
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available Ofloxacin tablet. The comparison of Dissolution profile of formulation F1 and 
markted formulation is depicted in Figure 17. 
 
 
Figure 17.Comparision of Dissolution profile of Ofloxacin loaded dendrimer tablet with 
Marketed Ofloxacin Tablet 
 
STABILITY STUDIES 
Table No. 9Physico-chemical characterization of formulation F1 during stability studies 
 
 
 
 
Figure 18.In-vitro dissolution study of F1 (A) after stability studies 
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